Unknown

Dataset Information

0

Sensitizing the cytotoxic action of Docetaxel induced by Pentoxifylline in a PC3 prostate cancer cell line.


ABSTRACT:

Background

Prostate cancer is one of the most frequently diagnosed types of cancers worldwide. In its initial period, the tumor is hormone-sensitive, but in advanced states, it evolves into a metastatic castration-resistant tumor. In this state, chemotherapy with taxanes such as Docetaxel (DTX) comprises the first line of treatment. However, the response is poor due to chemoresistance and toxicity. On the other hand, Pentoxifylline (PTX) is an unspecific inhibitor of phosphodiesterases; experimental, and clinically it has been described as sensitizing tumor cells to chemotherapy, increasing apoptosis and decreasing senescence. We study whether the PTX sensitizes prostate cancer cells to DTX for greater effectiveness.

Methods

PC3 human prostate cancer cells were treated in vitro at different doses and times with PTX, DTX, or their combination. Viability was determined by the WST-1 assay by spectrophotometry, cell cycle progression, apoptosis, generic caspase activation and senescence by flow cytometry, DNA fragmentation and caspases-3, -8, and -9 activity by ELISA.

Results

We found that PTX in PC3 human prostate cancer cells induces significant apoptosis per se and increases that generated by DTX, while at the same time it reduces the senescence caused by the chemotherapy and increases caspases-3,-8, and -9 activity in PTX?+?DTX-treated cells. Both treatments blocked the PC3 cell in the G1 phase.

Conclusions

Our results show that PTX sensitizes prostate tumor cells to apoptosis induced by DTX. Taken together, the results support the concept of chemotherapy with rational molecular bases.

SUBMITTER: Cancino-Marentes ME 

PROVIDER: S-EPMC7953714 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Background</h4>Prostate cancer is one of the most frequently diagnosed types of cancers worldwide. In its initial period, the tumor is hormone-sensitive, but in advanced states, it evolves into a metastatic castration-resistant tumor. In this state, chemotherapy with taxanes such as Docetaxel (DTX) comprises the first line of treatment. However, the response is poor due to chemoresistance and toxicity. On the other hand, Pentoxifylline (PTX) is an unspecific inhibitor of phosphodiesterases;  ...[more]

Similar Datasets

| S-EPMC6600328 | biostudies-literature
| S-EPMC2529074 | biostudies-literature
| S-EPMC7002631 | biostudies-literature
| S-EPMC4007720 | biostudies-literature
| S-EPMC5500835 | biostudies-other
| S-EPMC3228252 | biostudies-literature
2017-11-01 | GSE106363 | GEO
| PRJEB17751 | ENA
| S-EPMC4275561 | biostudies-literature
| S-EPMC4200097 | biostudies-other